ACURA PHARMACEUTICALS, INC

Form 4

August 22, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

may continue. See Instruction 1(b).

obligations

(Print or Type Responses)

(Last)

1. Name and Address of Reporting Person *

(First)

CARE CAPITAL II LLC

2. Issuer Name and Ticker or Trading

Symbol

ACURA PHARMACEUTICALS, INC [ACUR.OB]

(Month/Day/Year)

3. Date of Earliest Transaction

08/20/2007

5. Relationship of Reporting Person(s) to

OMB

Number:

Expires:

response...

Estimated average

burden hours per

OMB APPROVAL

3235-0287

January 31,

2005

0.5

Issuer

below)

(Check all applicable)

X__ 10% Owner _ Other (specify

C/O CARE CAPITAL LLC, 47 **HULFISH STREET, SUITE 310**

> (Street) 4. If Amendment, Date Original

(Middle)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Director

Officer (give title

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

PRINCETON, NJ 08542

(City)	(State)	(Zip) Tal	ble I - Non	-Derivative Sec	urities	Acqui	red, Disposed o	f, or Benefici	ally Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securities A oner Disposed of (Instr. 3, 4 and	(D)	d (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock							1,045,197	I	By subsidiary (1)
Common Stock							71,705	I	By subsidiary (2)
Common Stock	08/20/2007		P	33,333,332	A	(3)	34,450,234	I	By subsidiaries (4)
Common	08/20/2007		P	38,125,924	A	<u>(5)</u>	72,576,158	I	Ву

Stock subsidiaries (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) of Disposed of (I (Instr. 3, 4, and	D)	Expiration Date		7. Title and Amount Underlying Securition (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Common Stock Warrants (right to buy)	\$ 0.34						05/05/2003	05/05/2010	Common Stock	140
Common Stock Warrants (right to buy)	\$ 0.34						05/05/2003	05/05/2010	Common Stock	9,6
Common Stock Warrants (right to buy)	\$ 0.34	08/20/2007		P	8,333,333		08/20/2007	08/20/2014	Common Stock	8,33
Common Stock Warrants (right to buy)	\$ 0.34	08/20/2007		Р	9,531,481		08/20/2007	08/20/2014	Common Stock	9,53

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
		X				

Reporting Owners 2

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 4

CARE CAPITAL II LLC C/O CARE CAPITAL LLC 47 HULFISH STREET, SUITE 310 PRINCETON, NJ 08542

CARE CAPITAL INVESTMENTS II LP C/O CARE CAPITAL LLC 47 HULFISH STREET, SUITE 310 PRINCETON, NJ 08542

Care Capital Offshore Investments II LP C/O CARE CAPITAL LLC 47 HULFISH STREET, SUITE 310 PRINCETON, NJ 08542

X

X

Signatures

/s/ Dennis Peterson, Attorney-in-fact

**Signature of Reporting Person

Date

/s/ Dennis Peterson, Attorney-in-fact for Care Capital II, LLC, its general partner

**Signature of Reporting Person

Date

/s/ Dennis Peterson, Attorney-in-fact for Care Capital II, LLC, its general partner

**Signature of Reporting Person

Date

08/22/2007

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person, as general partner of Care Capital Investments II, L.P., the direct owner of the reported securities, beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
- The Reporting Person, as general partner of Care Capital Offshore Investments II, L.P., the direct owner of the reported securities, (2) beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of its
- (2) beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
- (3) The reported securities are included within 8,333,333 Units of Acura Pharmaceuticals, Inc. purchased by GCE Holdings LLC for \$1.08 per Unit.
- The Reporting Person, as general partner of each of Care Capital Investments II, L.P. and Care Capital Offshore Investments II, L.P., each of which is a member of GCE Holdings LLC, the direct owner of the reported securities, beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
- The reported securities are included within 9,531,481 Units of Acura Pharmaceuticals, Inc. received by GCE Holdings LLC in satisfaction of the outstanding aggregate of \$10.294 million in principal amount under Acura Pharmaceuticals, Inc.'s outstanding bridge loan indebtedness.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3